News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The drug will be manufactured at the group’s topical facility at Ahmedabad
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Subscribe To Our Newsletter & Stay Updated
